Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation

References

• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi: 10.3322/caac.21763.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute: surveillance Epidemiology and End Results. Cancer Stat Facts: prostate Cancer. 2022.
   Google Scholar
• Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9. doi: 10.1038/s41572-020-00243-0.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Hormone Therapy for Prostate Cancer. 2021.
   Google Scholar
• Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32(49):5501–5511. doi: 10.1038/onc.2013.206.
   PubMed Web of Science ®Google Scholar
• Moreira DM, Howard LE, Sourbeer KN, et al. Predictors of time to metastasis in castration-resistant prostate cancer. Urology. 2016;96:171–176. doi: 10.1016/j.urology.2016.06.011.
   PubMed Web of Science ®Google Scholar
• Lowrance W, Dreicer R, Jarrard DF, et al. Updates to advanced prostate cancer: AUA/SUO guideline (2023). J Urol. 2023;209(6):1082–1090. doi: 10.1097/JU.0000000000003452.
   PubMed Web of Science ®Google Scholar
• Lowrance WT, Murad MH, Oh WK, et al. Castration-resistant prostate cancer: AUA guideline amendment 2018. J Urol. 2018;200(6):1264–1272. doi: 10.1016/j.juro.2018.07.090.
   PubMed Web of Science ®Google Scholar
• Chi KN, Rathkopf D, Smith MR, et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol. 2023;41(18):3339–3351. doi: 10.1200/JCO.22.01649.
   PubMed Web of Science ®Google Scholar
• Clarke N, Armstrong A, Thiery-Vuillemin A, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1(9). doi: 10.1056/EVIDoa2200043.
   PubMedGoogle Scholar
• Wu B, Li SS, Song J, et al. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population. J Med Econ. 2020;23(1):54–63. doi: 10.1080/13696998.2019.1678171.
   PubMed Web of Science ®Google Scholar
• Appukkuttan S, Tangirala K, Babajanyan S, et al. A retrospective claims analysis of advanced prostate cancer costs and resource use. Pharmacoecon Open. 2020;4(3):439–447. doi: 10.1007/s41669-019-00185-8.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutical Companies of Johnson & Johnson. U.S. FDA approves expanded ZYTIGA® indication for treatment of metastatic castration-resistant prostate cancer. 2012.
   Google Scholar
• Astellas. U.S. FDA approves new indication for the use of XTANDI® (enzalutamide) capsules for patients with metastatic castration-resistant prostate cancer. 2014.
   Google Scholar
• AstraZeneca and Merck & Co. I. Lynparza approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer. 2020.
   Google Scholar
• Janssen Pharmaceutical Companies of Johnson & Johnson. U.S. FDA approves AKEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet for the treatment of patients with BRCA-positive metastatic castration-resistant prostate cancer. 2023.
   Google Scholar
• Ma X, Long L, Moon S, et al. Comparison of population characteristics in real-world clinical oncology databases in the US: flatiron health, SEER, and NPCR. medRxiv. 2020; 2020.03.16.20037143.
   Google Scholar
• Birnbaum B, Nussbaum N, Seidl-Rathkopf K, et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. arXiv preprint arXiv:2001097652020. 2020.
   Google Scholar
• Datavant. Overview of Datavant’s de-identification and linking technology for structured data. 2020.
   Google Scholar
• Komodo Health Solutions. Imputing allowed amounts development and validation of an encounter-level allowed amount imputation model. 2023.
   Google Scholar
• US Department of Health and Human Services. 45 CFR 46: pre-2018 requirements. 2021.
   Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197. doi: 10.1056/NEJMoa1207506.
   PubMed Web of Science ®Google Scholar
• Rathkopf DE, Smith MR, De Bono JS, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014;66(5):815–825. doi: 10.1016/j.eururo.2014.02.056.
   PubMed Web of Science ®Google Scholar
• Freedland S, Davis M, Epstein A, et al. Healthcare costs in men with metastatic castration-resistant prostate cancer: an analysis of US medicare Fee-For-service claims. Adv Ther. 2023;40(10):4480–4492. Online ahead of print. doi: 10.1007/s12325-023-02572-4.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute: cancer Trends Progress Report. Financial Burden of Cancer Care. 2023.
   Google Scholar
• Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–160. doi: 10.1016/S1470-2045(14)71205-7.
   PubMed Web of Science ®Google Scholar
• Congressional Budget Office. The prices that commercial health insurers and Medicare pay for hospitals’ and physicians’ services. 2022.
   Google Scholar
• Lopez E, Neuman T, Jacobson G, et al. How much more than Medicare do private insurers pay? A review of the literature. Issue brief. Kaiser Family Foundation; 2020.
   Google Scholar
• Meiselbach MK, Wang Y, Xu J, et al. Hospital prices for commercial plans are twice those for medicare advantage plans when negotiated by the same insurer. Health Aff (Millwood). 2023;42(8):1110–1118. doi: 10.1377/hlthaff.2023.00039.
   PubMed Web of Science ®Google Scholar
• Tomicki S, Dieguez G, Latimer H, et al. Real-World cost of care for commercially insured versus medicare patients with metastatic pancreatic cancer who received guideline-recommended therapies. Am Health Drug Benefits. 2021;14(2):70–78.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154. doi: 10.1016/S0140-6736(10)61389-X.
   PubMed Web of Science ®Google Scholar
• Wen L, Yao J, Valderrama A. Evaluation of treatment patterns and costs in patients with prostate cancer and bone metastases. J Manag Care Spec Pharm. 2019;25(3-b Suppl):S1–S11. doi: 10.18553/jmcp.2019.25.3-b.s1.
   PubMed Web of Science ®Google Scholar
• Lavallee L, Morash C, Saad F, et al. Real-world management of metastatic castration-resistant prostate cancer (mCRPC): a national multicenter cohort study. J Clin Oncol. 2022;40(6_suppl):252–252. doi: 10.1200/JCO.2022.40.6_suppl.252.
   PubMedGoogle Scholar
• Shore ND, Ionescu-Ittu R, Laliberté F, et al. Beyond frontline therapy with abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: a real-world US study. Clin Genitourin Cancer. 2021;19(6):480–490. doi: 10.1016/j.clgc.2021.07.009.
   PubMed Web of Science ®Google Scholar
• George DJ, Sartor O, Miller K, et al. Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States. Clin Genitourin Cancer. 2020;18(4):284–294. doi: 10.1016/j.clgc.2019.12.019.
   PubMed Web of Science ®Google Scholar
• Medicare.gov. Costs in the coverage gap. 2023.
   Google Scholar